Construction of self-assembled nanoparticle tumor vaccine OVA<sub>257-264</sub>-mi3 and evaluation of its protective efficacy

Yuan CHEN; Chen GAO; Yuhang LI; Zhiyuan CUI; Xin CHENG; Yi ZHANG; Bo YU; Jiang GU; Xian YANG

doi:10.16016/j.2097-0927.202401050

您当前的位置：

首页 >

文章列表页 >

Construction of self-assembled nanoparticle tumor vaccine OVA_257-264-mi3 and evaluation of its protective efficacy

Basic Medicine | 更新时间：2026-01-09

- Construction of self-assembled nanoparticle tumor vaccine OVA_257-264-mi3 and evaluation of its protective efficacy
- Journal of Army Medical University Vol. 46, Issue 12, Pages: 1361-1368(2024)
- 作者机构：
  
  1.401331 重庆，重庆师范大学生命科学学院
  2.400038 重庆，陆军军医大学(第三军医大学)：药学与检验医学系
  3.400038 重庆，陆军军医大学(第三军医大学)：第一附属医院骨科
- 作者简介：
- 基金信息：
  
  the National Key R&D Program(2021YFC2301405)
- DOI：10.16016/j.2097-0927.202401050
  CLC： R392-33;R392.7;R979.19
- Received：14 January 2024，
  
  Revised：2024-02-25，
  
  Published：30 June 2024
- 稿件说明：
移动端阅览
Yuan CHEN, Chen GAO, Yuhang LI, et al. Construction of self-assembled nanoparticle tumor vaccine OVA_257-264-mi3 and evaluation of its protective efficacy[J]. Journal of Army Medical University, 2024, 46(12): 1361-1368.
DOI：

Yuan CHEN, Chen GAO, Yuhang LI, et al. Construction of self-assembled nanoparticle tumor vaccine OVA_257-264-mi3 and evaluation of its protective efficacy[J]. Journal of Army Medical University, 2024, 46(12): 1361-1368. DOI： 10.16016/j.2097-0927.202401050.

摘要

目的

构建SpyCatcher-mi3纳米颗粒疫苗递送载体，评价其在增强卵清蛋白CD8

T细胞表位肽OVA

257-264

免疫原性和在小鼠荷瘤模型中免疫保护效果。

方法

SpyCatcher-mi3蛋白由大肠杆菌表达，依次经亲和层析、阴离子交换层析纯化得到；合成OVA

257-264

-SpyTag多肽，通过SpyTag/SpyCatcher蛋白质连接系统构建纳米颗粒OVA

257-264

-mi3；通过细胞溶血实验和细胞毒性实验评价OVA

257-264

-mi3体外安全性，记录小鼠体重变化和镜检脏器组织切片HE染色评价OVA

257-264

-mi3体内安全性；将6~8周龄，18~20 g，SPF级，雌性C57BL/6小鼠按随机数字表法分为OVA

257-264

-mi3组、OVA

257-264

组和Control组，每组14只，分别于第0、14、28天免疫小鼠，末次免疫后第14天通过ELISpot检测其脾脏淋巴细胞中IFN-γ分泌细胞数量评价其免疫原性；在小鼠荷瘤模型上通过核磁共振成像等手段评价纳米颗粒疫苗OVA

257-264

-mi3的保护效果。

结果

SpyCatcher-mi3和OVA

257-264

-mi3均自组装形成均一稳定的纳米颗粒，平均粒径约为43.8 nm和91.3 nm；OVA

257-264

-mi3在体内外均具有良好的安全性；OVA

257-264

-mi3组小鼠每1×10

个脾脏淋巴细胞中IFN-γ分泌细胞数量达253，显著高于OVA

257-264

组(

＜0.05)；OVA

257-264

-mi3组小鼠第22天荷瘤体积约151.1 mm

，显著小于OVA

257-264

组(

＜0.05)，且观察期内生存率达60%，显著高于OVA

257-264

组(

＜0.05)。

结论

成功构建了纳米颗粒疫苗OVA

257-264

-mi3，其增强肿瘤抗原表位肽OVA

257-264

免疫原性，在小鼠荷瘤模型中保护效果良好，为肿瘤新抗原疫苗的研究提供了理论基础。

Abstract

Objective

To construct SpyCatcher-mi3 nanoparticle vaccine delivery vectors

evaluate their role in enhancing the immunogenicity of the ovalbumin CD8

T-cell epitope peptide

OVA

257-264

and determine its protective effect in a model which mice were immunized and subcutaneously challenged with E.G7-OVA tumor cells.

Methods

SpyCatcher-mi3 proteins were expressed by

E.coli

and purified by affinity chromatography and anion exchange chromatography sequentially. OVA

257-264

-SpyTag peptide was obtained by synthesis. The OVA

257-264

-mi3 nanoparticles were produced by the SpyTag/SpyCatcher system. The toxicity of OVA

257-264

-mi3 was evaluated using hemolysis assay

CCK-8 assay and mouse experiment. A total of 42 female SPF-grade C57BL/6 mice (6~8 weeks old

18~20 g) were randomly divided into OVA

257-264

-mi3

OVA

257-264

and control groups

with 14 mice in each group. Then the mice in each group were immunized on days 0

14 and 28. In 14 d after the last immunization

the amounts of spot-forming cells (SFCs

indicating IFN-γ secreting cells in splenic lymphocytes) were determined using ELISpot assay to evaluate their immunogenicity. After the immunized mice were subcutaneously implanted with E.G7-OVA

tumor cells

the antitumor effect of the vaccine in prophylactic xenograft tumor model was evaluate by observing tumor volumes with a caliper and tumor growth with MRI.

Results

Both SpyCatcher-mi3 and OVA

257-264

-mi3 could be self-assembled to form homogeneous and stable nanoparticles

with an average particle size of about 43.8 and 91.3 nm

respectively. The OVA

257-264

-mi3 was safe for

in vitro

and

in vivo

toxicity evaluation. The number of IFN-γ secreting cells per 1×10

splenic lymphocytes reached 253 in the OVA

257-264

-mi3 group of mice

significantly higher than that in the OVA

257-264

group and the Control group (

0.05). The tumor volume of mice in the OVA

257-264

-mi3 group was about 151.1 mm

on day 22

which was significantly smaller than that of the OVA

257-264

group and the Control group (

0.05)

and the survival rate during the observation period reached 60%

which was significantly higher than that of the OVA

257-264

groups (

0.05).

Conclusion

Nanoparticle vaccine OVA

257-264

-mi3 is successfully constructed

and it shows enhancing effect on the immunogenicity of the antigen epitope peptide

and exerts protective effect on prophylactic xenograft tumor model

providing a theoretical basis for the research of tumor neoantigen vaccines.

关键词

Keywords

references

BERRAONDO P, SANMAMED M F, OCHOA M C, et al . Cytokines in clinical cancer immunotherapy[J ] . Br J Cancer, 2019, 120(1): 6-15. DOI: 10.1038/s41416-018-0328-y.

BENCI J L, JOHNSON L R, CHOA R, et al . Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade[J ] . Cell, 2019, 178(4): 933-948. e14. DOI: 10.1016/j.cell.2019.07.019.

ADACHI K, KANO Y, NAGAI T, et al . IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J ] . Nat Biotechnol, 2018, 36(4): 346-351. DOI: 10.1038/nbt.4086.

PEREZ C R, DE PALMA M. Engineering dendritic cell vaccines to improve cancer immunotherapy[J]. Nat Commun, 2019, 10(1): 5408. DOI: 10.1038/s41467-019-13368-y.

CHEN F M, WANG Y J, GAO J, et al . Nanobiomaterial-based vaccination immunotherapy of cancer[J ] . Biomaterials, 2021, 270: 120709. DOI: 10.1016/j.biomaterials.2021.120709.

XIE N, SHEN G B, GAO W, et al . Neoantigens: promising targets for cancer therapy[J ] . Signal Transduct Target Ther, 2023, 8(1): 9. DOI: 10.1038/s41392-022-01270-x.

DUNN G P, BRUCE A T, IKEDA H, et al . Cancer immunoediting: from immunosurveillance to tumor escape[J ] . Nat Immunol, 2002, 3(11): 991-998. DOI: 10.1038/ni1102-991.

PENG M, MO Y Z, WANG Y A, et al . Neoantigen vaccine: an emerging tumor immunotherapy[J ] . Mol Cancer, 2019, 18(1): 128. DOI: 10.1186/s12943-019-1055-6.

KANG Y F, SUN C, ZHUANG Z, et al . Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates[J ] . ACS Nano, 2021, 15(2): 2738-2752. DOI: 10.1021/acsnano.0c08379.

COHEN A A, VAN DOREMALEN N, GREANEY A J, et al . Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models[J ] . Science, 2022, 377(6606): eabq0839. DOI: 10.1126/science.abq0839.

LEE Y, KIM M, KANG J Y, et al . Protein cages engine ered for interaction-driven selective encapsulation of biomolecules[J ] . ACS Appl Mater Interfaces, 2022, 14(31): 35357-35365. DOI: 10.1021/acsami.2c06924.

ZAKERI B, FIERER J O, CELIK E, et al . Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin[J ] . Proc Natl Acad Sci U S A, 2012, 109(12): E690-E697. DOI: 10.1073/pnas.1115485109.

CHOU P Y, LIN S Y, WU Y N, et al . Glycosylation of OVA antigen-loaded PLGA nanoparticles enhances DC-targeting for cancer vaccination[J ] . J Control Release, 2022, 351: 970-988. DOI: 10.1016/j.jconrel.2022.10.002.

BRUUN T U J, ANDERSSON A C, DRAPER S J, et al . Engineering a rugged nanoscaffold to enhance plug-and-display vaccination[J ] . ACS Nano, 2018, 12(9): 8855-8866. DOI: 10.1021/acsnano.8b02805.

SHAHBAZI M A, SANTOS H A. Revolutionary impact of nanovaccines on immunotherapy[J]. Eur J Mol Clin Med, 2014, 2(2): 44. DOI: 10.1016/j.nhtm.2014.11.058.

EL-SAY K M, EL-SAWY H S. Polymeric nanoparticles: promising platform for drug delivery[J]. Int J Pharm, 2017, 528(1/2): 675-691. DOI: 10.1016/j.ijpharm.2017.06.052.

TAN T K, RIJAL P, RAHIKAINEN R, et al . A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses[J ] . Nat Commun, 2021, 12(1): 542. DOI: 10.1038/s41467-020-20654-7.

LIU Z H, XU H L, HAN G W, et al . A self-assembling nanoparticle: implications for the development of thermostable vaccine candidates[J ] . Int J Biol Macromol, 2021, 183: 2162-2173. DOI: 10.1016/j.ijbiomac.2021.06.024.

HAN J A, KANG Y J, SHIN C, et al . Ferritin protein cage nanoparticles as versatile antigen delivery nanoplatforms for dendritic cell (DC)-based vaccine development[J ] . Nanomed-Nanotechnol Biol Med, 2014, 10(3): 561-569. DOI: 10.1016/j.nano.2013.11.003.

DING B B, ZHENG P, JIANG F, et al . MnO x nanospikes as nanoadjuvants and immunogenic cell death drugs with enhanced antitumor immunity and antimetastatic effect[J ] . Angew Chem Int Ed, 2020, 59(38): 16381-16384. DOI: 10.1002/anie.202005111..

WANG S H, GAO J, WANG Z J. Outer membrane vesicles for vaccination and targeted drug delivery[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2019, 11(2): e1523. DOI: 10.1002/wnan.1523.

XIANG S D, SCHOLZEN A, MINIGO G, et al . Pathogen recognition and development of particulate vaccines: does size matter?[J ] . Methods, 2006, 40(1): 1-9. DOI: 10.1016/j.ymeth.2006.05.016.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

GAO Chen

LI Yuhang

CUI Zhiyuan

CHENG Xin

ZHANG Yi

YU Bo

GU Jiang

YANG Xian

Related Institution

Department of Microbiology and Biochemical Pharmacy,Faculty of Pharmacy and Laboratory Medicine

Department of Orthopaedics,The First Affiliated Hospital, Army Medical University(Third Military Medical University)

⁰

Construction of self-assembled nanoparticle tumor vaccine OVA257-264-mi3 and evaluation of its protective efficacy

DOI：10.16016/j.2097-0927.202401050

摘要

Abstract

关键词

Keywords

references

Construction of self-assembled nanoparticle tumor vaccine OVA_257-264-mi3 and evaluation of its protective efficacy